Biogen Inc vs Paycom Software Inc — how do they compare? Biogen Inc trades at $204.51 (market cap $30.13B), while Paycom Software Inc trades at $204.7 (market cap $9.57B). The key difference: Biogen Inc is far larger — about 3.1× Paycom Software Inc's market cap, and Paycom Software Inc pays a 0.71% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PAYC | |
|---|---|---|
Market Cap | $30.13B | $9.57B |
Sector | Health | Technology |
52-Week High | $216.63 | $233.89 |
52-Week Low | $128.93 | $113.59 |
Enterprise Value | $37.20B | $10.35B |
Dividend Yield | — | 0.71% |
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Paycom Software (PAYC) trades at $209.22, down 1.98% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings of $2.78 per share, beating estimates, and raised its full-year outlook, driven by 10% revenue growth and AI-driven demand. Fundamentals show robust profitability with a 22.78% net income margin and 41.09% ROE, though valuation multiples like P/E of 22.46 are elevated. Recent news highlights operational efficiency and dividend declarations.
The outlook remains positive given consistent earnings beats and raised guidance, but risks include high valuation and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting moderate upside. Investors should weigh strong fundamentals against potential overvaluation and market sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →